1394 V •Vfi, v' Figure I. Lung metastases specimen: significant overexpression of HER2/neu (Immunhistochemical staining ABC-test; Novocasta Inc.). patients, a small number remain who cannot be cured with current treatment strategies. For those patients, new treatment options must be explored. Accordingly, HER2/neu may serve as a new target in those patients who overexpress the c-erbB oncogene. The present observation indicates that the use of molecular targeted therapy should be further investigated, possibly in combination with chemotherapy, in order to fully define its role not only in the treatment of both refractory and chemosensitive testicular cancer patients, but also in patients with other tumors overexpressing HER2/neu. C. Kollmannsberger, 1 H. PreBler, 2 F. Mayer, 1 L. Kanz 1 & C. Bokemeyer 1 Department of Hematology/Oncology, University of Tuebingen Medical Center; 2 Department of Pathology, University of Tubingen, Tubingen, Germany References 1. Bokemeyer C, Kollmannsberger C, Harstrick A et al. Treatment of patients with cisplatin refractory testicular germ-cell cancer. Int J Cancer 1999 (in press). 2. Henley J, Einhorn LH. C-erbB-2 (Her-2-neu) overexpression in recurrent germ-cell tumors. Proc Am Soc Clin Oncol 1999; 18: 341a (Abstr 1313). 3. Klapper LN, Vaisman N, Hurwitz E et al. A subclass of tumor- inhibitory monoclonal antibodies to Erb2/HER2 blocks crosstalk with growth factor receptor. Oncogene 1997; 14: 2099-109. Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen) CMF combination chemotherapy is one of the most effective and safe regimens used as adjuvant systemic treatment for breast cancer. There are limited data in the literature of hepatic toxicity from adjuvant chemotherapy. Moreover, there are no published reports focusing on liver toxicity from combination chemotherapy with cyclophosphamide, methotrexate, and flu- orouracil (CMF), with M and F given i.v. on days 1 and 8 every four weeks (classical CMF). We therefore, evaluated retrospec- tively serial liver function tests (LFT) of 264 patients treated with adjuvant CMF after surgery for early breast cancer, to asses the incidence and severity of hepatic toxicity. Patients were treated at our institution from 11 July 1995 to 26 July 1999 according to the following regimen (oral cyclo- phosphamide 100 mg/m 2 (Endoxan-Asta®; Asta Medica, Italy), days 1-14, methotrexate 40 mg/m 2 (Methotrexate®; Teva, Italy) and 5-fluorouracil 600 mg/m 2 (Fluoro-Uracile®; Teva, Italy) i.v., both on days die 1, 8). Each patient had a baseline history and a physical examination, serum alkaline phosphatase, transaminases (SGOT, SGPT), bilirubin total, lactate dehydro- genase determinations, a chest X-ray, a 99mTC phosphate bone scan and a liver ultrasound. Liver functions tests were repeated at least every eight weeks. All patients received Granisetron and Dexametazone as prophylaxis against nausea and vomiting, but no other medicines were routinely given. All patients were tested for HBV markers and anti-HCV antibodies at presentation (three patients were positive for HBsAg and anti-HBsAg and three for HCV). Median age was 49 (range 25-74 years). No evidence of previous history of liver disease or evidence of functional liver abnormality was detected at baseline. Two patients previously received neoadjuvant chemo- therapy and ninety-four patients have received four cycles of AC or EC schedule (doxorubicin 60 mg/m 2 (Adriblastina K ; Downloaded from https://academic.oup.com/annonc/article-abstract/10/11/1394/169511 by guest on 27 July 2018